Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: Results from the Tigecycline in Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1414-1417

  Liu, Jien Wei ^a   Ko, Wen Chien ^b   Huang, Cheng Hua ^c   Liao, Chun Hsing ^d   Lu, Chin Te ^e   Chuang, Yin Ching ^f   Tsao, Shih Ming ^g   Chen, Yao Shen ^h   Liu, Yung Ching ^h,i,j   Chen, Wei Yu ^k   Jang, Tsrang Neng ^k   Lin, Hsiu Chen ^j   Chen, Chih Ming ^l   Shi, Zhi Yuan ^m   Pan, Sung Ching ⁿ   Yang, Jia Ling ⁿ   Kung, Hsiang Chi ⁿ   Liu, Chun Eng ^o   Cheng, Yu Jen ^o   Chen, Yen Hsu ^p   Lu, Po Liang ^p   Sun, Wu ^q   Wang, Lih Shinn ^r   Yu, Kwok Woon ^s   Chiang, Ping Cherng ^t   Lee, Ming Hsun ^t   Lee, Chun Ming ^u   Hsu, Gwo Jong ^v   Hsueh, Po Ren ⁿ   more..

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c CATHAY GENERAL HOSPITAL   (Taiwan)

^d FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^e LOTUNG POH AI HOSPITAL   (Taiwan)

^f CHI MEI MEDICAL CENTER   (Taiwan)

^g CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^h KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

ⁱ TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^j TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^k SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^l TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^m TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

ⁿ NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^o CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^p KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^q Pao Chien Hospital   (Taiwan)

^r BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^s TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^t Chang Gung Medical Foundation Linkou Branch   (Taiwan)

^u MACKAY MEMORIAL HOSPITAL   (Taiwan)

^v CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; DISK DIFFUSION; ESCHERICHIA COLI; FOOD AND DRUG ADMINISTRATION; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TAIWAN; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; KLEBSIELLA PNEUMONIAE; LONGITUDINAL STUDIES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; TAIWAN; VANCOMYCIN;

EID: 84863121492     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05879-11     Document Type: Article

References (24)

1. Boucher HW, et al. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
2. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial disk susceptibility tests: approved standard M2-A9, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A7, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; 21st informational supplement, M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
5. CLSI/NCCLS. 2001. Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline, 2nd ed. NCCLS document M23-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
6. European Society of Clinical Microbiology Infectious Diseases. 2011. Clinical breakpoints. In European Committee on Antimicrobial Susceptibility Testing (ed). http://www.eucast.org/.
7. Reference deleted.
8. Farmer JJ, III. 1999. Enterobacteriaceae: introduction and identification, p 442-458. In Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (ed), Manual of clinical microbiology, 7th ed. ASM Press, Washington, DC.
9. Hope R, et al. 2005. Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines. J. Antimicrob. Chemother. 56:1042-1046. (Pubitemid 43009817)
10. Hsueh PR. 2008. Tigecycline in-vitro surveillance in Taiwan (TIST). Int. J. Antimicrob. Agents 32(Suppl 3):173.
11. Kloos W, Bannerman TL. 1999. Staphylococcus and Micrococcus, p 244-282. In Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (ed), Manual of clinical microbiology, 7th ed. ASM Press, Washington, DC.
12. Lee CH, et al. 2010. Microbiologic and clinical implications of bacteremia due to extended-spectrum-β-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC. Antimicrob. Agents Chemother. 54:5395-5398.
13. Lee CH, Su LH, Tang YF, Liu JW. 2006. Treatment of ESBL producing Klebsiella pneumoniae bacteremia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. J. Antimicrob. Chemother. 58:1074-1077.
14. Liao CH, et al. 2006. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan determined by the broth microdilution and disk diffusion methods. Int. J. Antimicrob. Agents 32(Suppl 3):192-196.
15. Liu JW, et al. 2008. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan. Int. J. Antimicrob. Agents 32(Suppl 3):188-191.
16. Liu JW, et al. 2010. Comparison of the Etest and broth microdilution methods for tigecycline susceptibility testing against clinical isolates of Acinetobacter baumannii from Taiwan. Int. J. Antimicrob. Agents 35:201-202. (Letter.)
17. Lu CT, et al. 2008. Nationwide surveillance in Taiwan of the in vitro activity of tigecycline against clinical isolates of extended-spectrum β-lactamase-producing Enterobacteriaceae. Int. J. Antimicrob. Agents 32(Suppl 3):179-183.
18. Norrby SR, Nord CE, Finch R. 2005. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect. Dis. 5:115-119. (Pubitemid 40174782)
19. Ruoff KL. 1999. Algorithm for identification of aerobic Gram-positive cocci, p 262-264. In Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (ed), Manual of clinical microbiology, 7th ed. ASM Press, Washington, DC.
20. Schreckenberger PC, von Graevenitz A. 1999. Acinetobacter, Achromobacter, Alcaligenes, Moraxella, Methylobacterium, and other nonfermentative Gram-negative rods, p 539-560. In Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (ed), Manual of clinical microbiology, 7th ed. ASM Press, Washington, DC.
21. Spellberg B, et al. 2008. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46:155-164. (Pubitemid 351269151)
22. Thamlikitkul V, Tiengrim S. 2008. Effect of different Mueller-Hinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp. J. Antimicrob. Chemother. 62:847-848.
23. Tsao SM, et al. 2008. Nationwide surveillance in Taiwan of the in vitro activity of tigecycline against clinical isolates of Gram-positive cocci. Int. J. Antimicrob. Agents 32(Suppl 3):184-187.
24. Turnidge JD, Ferraro MJ, Jorgensen JH. 2011. Susceptibility testing methods: general considerations, p 1115-1121. In Versalovic J, et al (ed). Manual of clinical microbiology, 10th ed, vol 1. ASM Press, Washington, DC.